Free Trial

Acrivon Therapeutics (ACRV) Institutional Ownership

Acrivon Therapeutics logo
$6.50 +0.12 (+1.88%)
(As of 11/20/2024 ET)

Institutional Ownership Changes (13F Filings) for Acrivon Therapeutics (NASDAQ:ACRV)

Current
Institutional Ownership
Percentage
71.62%
Number of
Institutional Buyers
(last 12 months)
13
Total
Institutional Inflows
(last 12 months)
$19.75M
Number of
Institutional Sellers
(last 12 months)
4
Total
Institutional Outflows
(last 12 months)
$674.56K
Get ACRV Insider Trade Alerts

Want to know when executives and insiders are buying or selling Acrivon Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

Skip Chart & View Institutional Buying and Selling Data

ACRV Institutional Buying and Selling by Quarter

Acrivon Therapeutics Major Shareholders & Ownership History

Reporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/19/2024 Barclays PLC33,306$233K0.0%+51.2%0.107%
11/16/2024 Geode Capital Management LLC302,103$2.12M0.0%-2.0%0.975%
11/15/2024 Barclays PLC33,306$233K0.0%+51.2%0.108%
11/15/2024 State Street Corp225,896$1.58M0.0%+26.4%0.729%
11/12/2024 Charles Schwab Investment Management Inc.116,253$814K0.0%-19.2%0.375%
10/10/2024 Exchange Traded Concepts LLC20,348$142K0.0%-52.5%0.066%
8/16/2024 Perceptive Advisors LLC5,360,858$31.09M0.7%+78.2%17.362%
8/14/2024 Marshall Wace LLP948,866$5.50M0.0%+58.8%3.073%
8/13/2024 Sands Capital Ventures LLC2,122,605$12.31M4.1%+28.4%6.874%
8/12/2024 XTX Topco Ltd10,493$61K0.0%N/A0.034%
8/9/2024 Renaissance Technologies LLC54,500$316K0.0%-46.9%0.177%
8/9/2024 Dimensional Fund Advisors LP10,066$58K0.0%N/A0.033%
8/1/2024 Rhumbline Advisers16,209$94K0.0%+48.9%0.052%
7/26/2024 Bank of New York Mellon Corp36,632$212K0.0%+50.1%0.119%
5/15/2024 Baker BROS. Advisors LP52,885$378K0.0%N/A0.234%
5/14/2024 American International Group Inc.6,016$43K0.0%+39.2%0.027%
5/10/2024 Vanguard Group Inc.507,185$3.63M0.0%+6.6%2.241%
1/5/2024 Exchange Traded Concepts LLC13,289$65K0.0%+34.0%0.060%
11/13/2023 Federated Hermes Inc.226,375$2.16M0.0%-25.6%1.020%
9/21/2023 Barclays PLC14,263$184K0.0%-16.0%0.065%
8/10/2023 AAF Wealth Management LLC10,678$138K0.1%N/A0.049%
7/20/2023 Exchange Traded Concepts LLC11,709$152K0.0%N/A0.053%
5/8/2023 Federated Hermes Inc.613,625$7.79M0.0%-25.5%2.798%
2/16/2023HealthCor Management L.P.284,201$3.27M3.0%N/A1.360%
2/14/2023 RA Capital Management L.P.4,810,508$55.42M1.1%N/A23.028%
2/13/2023 Sands Capital Ventures LLC1,652,605$19.04M5.2%N/A7.913%
2/10/2023 NEA Management Company LLC481,677$4.44M0.2%N/A2.306%
2/1/2023 Bank of Montreal Can42,444$545K0.0%N/A0.203%
(Data available from 1/1/2016 forward)

ACRV Institutional Ownership - Frequently Asked Questions

Who are the largest shareholders of ACRV shares?

During the previous two years, 22 institutional investors and hedge funds held shares of Acrivon Therapeutics. The most heavily invested institutionals were RA Capital Management L.P. ($55.42M), Perceptive Advisors LLC ($31.09M), Sands Capital Ventures LLC ($12.31M), Marshall Wace LLP ($5.50M), NEA Management Company LLC ($4.44M), Vanguard Group Inc. ($3.63M), and HealthCor Management L.P. ($3.27M).Learn more on ACRV's institutional investors.

What percentage of Acrivon Therapeutics stock is owned by institutional investors?

71.62% of Acrivon Therapeutics stock is owned by institutional investors. Learn more on ACRV's institutional investor holdings.

Which institutional investors have been buying Acrivon Therapeutics stock?

Of the 18 institutional investors that purchased Acrivon Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: RA Capital Management L.P. ($4.81M), Perceptive Advisors LLC ($2.35M), Sands Capital Ventures LLC ($2.12M), NEA Management Company LLC ($481.68K), Marshall Wace LLP ($351.40K), HealthCor Management L.P. ($284.20K), and Baker BROS. Advisors LP ($52.89K).

How much institutional buying is happening at Acrivon Therapeutics?

Institutional investors have bought a total of 10,665,254 shares in the last 24 months. This purchase volume represents approximately $103.81M in transactions.

Which Acrivon Therapeutics major shareholders have been selling company stock?

The following institutional investors have sold Acrivon Therapeutics stock in the last 24 months: Federated Hermes Inc. ($287.71K), Renaissance Technologies LLC ($48.10K), Charles Schwab Investment Management Inc. ($27.71K), Exchange Traded Concepts LLC ($22.52K), Geode Capital Management LLC ($6.29K), and Barclays PLC ($2.72K).

How much institutional selling is happening at Acrivon Therapeutics?

Institutional investors have sold a total of 395,042 shares in the last 24 months. This volume of shares sold represents approximately $4.12M in transactions.



This page (NASDAQ:ACRV) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners